Who
Eric Pauwels
Chief Business Officer
Company insider
Files Form 4 as: Chief Business Officer, PTC Therapeutics; President, NPS Pharma Int'l, Nps Pharmaceuticals; SVP Chief Marketing Officer, Accuray.
In numbers
- Trades disclosed
- 173
- Buys
- 0
- Sells
- 41
- Bought
- $0
- Sold
- $15.2M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 28 Feb 2011
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $278K3,711 at $75.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code M | $316K17,566 at $18.01 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.3M17,566 at $75.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | —17,566 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | —17,566 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $278K3,711 at $75.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code M | $316K17,566 at $18.01 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.3M17,566 at $75.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $209K3,019 at $69.36 | filing |
| 18 Feb 2026filed 20 Feb 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $209K3,019 at $69.36 | filing |
| 12 Jan 2026filed 12 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $81K1,024 at $78.70 | filing |
| 12 Jan 2026filed 12 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $81K1,024 at $78.70 | filing |
| 9 Jan 2026filed 12 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $133K1,722 at $77.41 | filing |
| 9 Jan 2026filed 12 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $133K1,722 at $77.41 | filing |
| 8 Jan 2026filed 12 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $196K2,561 at $76.42 | filing |
| 8 Jan 2026filed 12 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $45K587 at $76.98 | filing |
| 8 Jan 2026filed 12 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $111K1,454 at $76.45 | filing |
| 8 Jan 2026filed 12 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $196K2,561 at $76.42 | filing |
| 8 Jan 2026filed 12 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $45K587 at $76.98 | filing |
| 8 Jan 2026filed 12 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $111K1,454 at $76.45 | filing |
News
PTC Therapeutics (NASDAQ:PTCT) & Aktis Oncology (NASDAQ:AKTS) Head to Head ContrastPTCT · dailypolitical.com · 19 Oct 2026PTC Therapeutics (NASDAQ:PTCT) Director Michael Schmertzler Sells 2,500 Shares of Company StockPTCT · tickerreport.com · 16 Oct 2026
0 headlines in the last 90 days name Eric Pauwels; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.